Hondramine tablets, containing components derived from bovine cartilage, offer a unique blend of proteins and nucleoproteins. These components selectively target cartilage cells, promoting normalized metabolic processes within chondrocytes and reducing the risk of various joint disorders. Clinical trials involving 120 patients with osteoarthritis of the knee, spinal osteochondrosis, and systemic osteoporosis demonstrated Hondramine's effectiveness. Efficacy was assessed based on subjective symptom improvement, objective laboratory and instrumental findings, and musculoskeletal functional status monitoring. Results showed that Hondramine, as part of a comprehensive treatment plan, significantly reduced pain and joint stiffness. The most notable effects were pain reduction and increased range of motion in affected joints. Patients experienced a substantial alleviation of persistent, treatment-resistant symptoms. While the clinical effect varied depending on disease stage (less pronounced in older patients), even these individuals reported highly favorable subjective improvements. Hondramine, a dietary supplement providing polypeptides and nucleic acids, is indicated for: degenerative-dystrophic joint and spinal diseases; post-joint and limb trauma; arthritides of various etiologies; systemic connective tissue diseases; post-extreme physical exertion; pre- and postoperative joint surgery; and systemic prevention of musculoskeletal disorders in elite athletes.
US: temporary delays — postal services aligning new import rules, 
EU: 1–2 weeks, 🌍 Worldwide: 1–4 weeks ✈️